Predicting new-onset HF in patients undergoing coronary or peripheral angiography: results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study

Nasrien E Ibrahim, Asya Lyass, Hanna K Gaggin, Yuyin Liu, Roland R J van Kimmenade, Shweta R Motiwala, Noreen P Kelly, Parul U Gandhi, Mandy L Simon, Arianna M Belcher, Jamie E Harisiades, Joseph M Massaro, Ralph B D'Agostino, James L Januzzi Jr, Nasrien E Ibrahim, Asya Lyass, Hanna K Gaggin, Yuyin Liu, Roland R J van Kimmenade, Shweta R Motiwala, Noreen P Kelly, Parul U Gandhi, Mandy L Simon, Arianna M Belcher, Jamie E Harisiades, Joseph M Massaro, Ralph B D'Agostino, James L Januzzi Jr

Abstract

Aims: Methods to identify patients at risk for incident HF would be welcome as such patients might benefit from earlier interventions.

Methods and results: From a registry of 1251 patients referred for coronary and/or peripheral angiography, we sought to identify independent predictors of incident HF during follow-up and develop a clinical and biomarker strategy to predict this outcome. There were 991 patients free of prevalent HF at baseline. Cox proportional hazard models were developed to predict adjudicated diagnosis of incident HF. Model discrimination and reclassification were evaluated. At follow-up, 177 (18%) developed new-onset HF. Independent predictors of new-onset HF included five clinical variables (age, male sex, heart rate, history of atrial fibrillation/flutter, and history of hypertension) and two biomarkers (amino-terminal pro-B type natriuretic peptide and ST2). The c-statistic for the model without biomarkers was 0.69; including biomarkers increased the c-statistic to 0.76 (P < 0.001). A score was developed from the model. Patients in the highest score quintile had shortest time to incident HF compared with lower quintiles (log-rank P < 0.001). Following 100 bootstrap iterations, internal validation was confirmed with Harrell's c-statistic of 0.77. Use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers at enrollment was associated with substantial attenuation of predictive value of the risk score.

Conclusions: Patients undergoing coronary/peripheral angiographic procedures are a population at high risk for incident HF. We describe an accurate clinical and biomarker strategy for predicting incident HF and possibly intervening in such patients (NCT00842868).

Keywords: Biomarker; Diagnosis; HF; Score.

© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Figures

Figure 1
Figure 1
Study flow diagram.
Figure 2
Figure 2
Time to first HF event based on quintiles of risk score. Patients in the highest score quintile had the shortest time to development of incident HF.

References

    1. Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res 2016; 118: 1723–1735.
    1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després J‐P, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB. Heart Disease and Stroke Statistics—2016 Update. A report from the American Heart Association. 2016; 133: e38–e360.
    1. Konstam MA, Desai AS. Home monitoring should be the central element in an effective program of heart failure disease management. Circulation 2012; 125: 820–827.
    1. Desai AS. Home monitoring heart failure care does not improve patient outcomes: looking beyond telephone‐based disease management. Circulation 2012; 125: 828–836.
    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: 1495–1539.
    1. Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PF, Levy D. Profile for estimating risk of heart failure. Arch Intern Med 1999; 159: 1197–1204.
    1. Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, Bauer DC, Satterfield S, Smith AL, Vaccarino V, Newman AB, Harris TB, Wilson PWF, Kritchevsky SB. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail 2008; 1: 125–133.
    1. Agarwal SK, Chambless LE, Ballantyne CM, Astor B, Bertoni AG, Chang PP, Folsom AR, He M, Hoogeveen RC, Ni H, Quibrera M, Rosamond WD, Russell SD, Shahar E, Heiss G. Prediction of incident heart failure in general practice: the ARIC study. Circulation: Heart Failure 2012.
    1. Horne BD, May HT, Kfoury AG, Renlund DG, Muhlestein JB, Lappé DL, Rasmusson KD, Bunch TJ, Carlquist JF, Bair TL, Jensen KR, Ronnow BS, Anderson JL. The Intermountain Risk Score (including the red cell distribution width) predicts heart failure and other morbidity endpoints. Eur J Heart Fail 2010; 12: 1203–1213.
    1. Kleber ME, Koller L, Goliasch G, Sulzgruber P, Scharnagl H, Silbernagel G, Grammer TB, Delgado G, Tomaschitz A, Pilz S, März W, Niessner A. Von Willebrand factor improves risk prediction in addition to N‐terminal pro–B‐type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction. Circ Heart Fail 2015; 8: 25–32.
    1. Koller L, Kleber M, Goliasch G, Sulzgruber P, Scharnagl H, Silbernagel G, Grammer T, Delgado G, Tomaschitz A, Pilz S, März W, Niessner A. C‐reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction. Eur J Heart Fail 2014; 16: 758–766.
    1. Gaggin HK, Bhardwaj A, Belcher A, Motiwala S, Gandhi PU, Simon M, Kelly N, Anderson A, Garasic JM, Danik S, Schwamm LH, Gerszten RE, van Kimmenade R, Januzzi J. Design, methods, baseline characteristics and interim results of the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. IJC of Metabolic & Endocrine 2014; 5: 11–18.
    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González‐Juanatey JR, Harjola V‐P, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Filippatos G, McMurray JJV, Aboyans V, Achenbach S, Agewall S, Al‐Attar N, Atherton JJ, Bauersachs J, John Camm A, Carerj S, Ceconi C, Coca A, Elliott P, Erol Ç, Ezekowitz J, Fernández‐Golfín C, Fitzsimons D, Guazzi M, Guenoun M, Hasenfuss G, Hindricks G, Hoes AW, Iung B, Jaarsma T, Kirchhof P, Knuuti J, Kolh P, Konstantinides S, Lainscak M, Lancellotti P, Lip GYH, Maisano F, Mueller C, Petrie MC, Piepoli MF, Priori SG, Torbicki A, Tsutsui H, van Veldhuisen DJ, Windecker S, Yancy C, Zamorano JL, Zamorano JL, Aboyans V, Achenbach S, Agewall S, Badimon L, Barón‐Esquivias G, Baumgartner H, Bax JJ, Bueno H, Carerj S, Dean V, Erol Ç, Fitzsimons D, Gaemperli O, Kirchhof P, Kolh P, Lancellotti P, Lip GYH, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Roffi M, Torbicki A, Vaz Carneiro A, Windecker S, Sisakian HS, Isayev E, Kurlianskaya A, Mullens W, Tokmakova M, Agathangelou P, Melenovsky V, Wiggers H, Hassanein M, Uuetoa T, Lommi J, Kostovska ES, Juillière Y, Aladashvili A, Luchner A, Chrysohoou C, Nyolczas N, Thorgeirsson G, Marc Weinstein J, Di Lenarda A, Aidargaliyeva N, Bajraktari G, Beishenkulov M, Kamzola G, Abdel‐Massih T, Čelutkienė J, Noppe S, Cassar A, Vataman E, Abir‐Khalil S, van Pol P, Mo R, Straburzyńska‐Migaj E, Fonseca C, Chioncel O, Shlyakhto E, Otasevic P, Goncalvesová E, Lainscak M, Díaz Molina B, Schaufelberger M, Suter T, Yılmaz MB, Voronkov L, Davies C. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–2200.
    1. Januzzi JL Jr, Sakhuja R, O'Donoghue M, Baggish AL, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo CAJ, Lloyd‐Jones DM. Utility of amino‐terminal pro‐brain natriuretic peptide testing for prediction of 1‐year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006; 166: 315–320.
    1. Dieplinger B, Januzzi JL Jr, Steinmair M, Gabriel C, Poelz W, Haltmayer M, Mueller T. Analytical and clinical evaluation of a novel high‐sensitivity assay for measurement of soluble ST2 in human plasma—the Presage™ ST2 assay. Clin Chim Acta 2009; 409: 33–40.
    1. Sullivan LM, Massaro JM, D'Agostino RB. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 2004; 23: 1631–1660.
    1. Miao Y, Cenzer IS, Kirby KA, Boscardin WJ. Estimating Harrell's optimism on predictive indices using bootstrap samples. SAS Global Forum 2013(504–2013).
    1. Kim H‐N, Januzzi JL. Natriuretic peptide testing in heart failure. Circulation 2011; 123: 2015–2019.
    1. Januzzi JL, Pascual‐Figal D, Daniels LB. ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. Am J Cardiol 2015; 115: 70B–75B.
    1. Brouwers FP, van Gilst WH, Damman K, van den Berg MP, Gansevoort RT, Bakker SJL, Hillege HL, van Veldhuisen DJ, van der Harst P, de Boer RA. Clinical risk stratification optimizes value of biomarkers to predict new‐onset heart failure in a community‐based cohort. Circ Heart Fail 2014; 7: 723–731.
    1. Goya Wannamethee S, Welsh P, Whincup PH, Lennon L, Papacosta O, Sattar N. N‐terminal pro brain natriuretic peptide but not copeptin improves prediction of heart failure over other routine clinical risk parameters in older men with and without cardiovascular disease: population‐based study. Eur J Heart Fail 2014; 16: 25–32.
    1. Anwaruddin S, Lloyd‐Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi JL. Renal function, congestive heart failure, and amino‐terminal pro‐brain natriuretic peptide measurement: results from the proBNP investigation of dyspnea in the emergency department (PRIDE) study. J Am Coll Cardiol 2006; 47: 91–97.
    1. van Kimmenade RRJ, Januzzi JL, Baggish AL, Lainchbury JG, Bayes‐Genis A, Richards AM, Pinto YM. Amino‐terminal pro‐brain natriuretic peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol 2006; 48: 1621–1627.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅